Results 181 to 190 of about 480,923 (314)

Minutes: Strategic Enrollment Management Subcommitte, November 15, 2017

open access: yes, 2017
University of Minnesota Duluth. Strategic Enrollment Management Subcommitte. (2017). Minutes: Strategic Enrollment Management Subcommitte, November 15, 2017.
University of Minnesota Duluth. Strategic Enrollment Management Subcommitte
core  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Minutes: Strategic Enrollment Management Subcommitte, April 4, 2018

open access: yes, 2018
University of Minnesota Duluth. Strategic Enrollment Management Subcommitte. (2018). Minutes: Strategic Enrollment Management Subcommitte, April 4, 2018.
University of Minnesota Duluth. Strategic Enrollment Management Subcommitte
core  

Remarkable Recovery After Delayed High‐Dose Methylprednisolone in a Rare Case of Penetrating Spinal Cord Injury

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Traumatic spinal cord injury (TSCI) caused by sharp‐force penetration is exceptionally rare, and the use of high‐dose methylprednisolone (MP) remains highly controversial, especially beyond the conventional 8‐h treatment window. This case report describes a 30‐year‐old male with acute incomplete TSCI following a knife stab wound to the right ...
Honghong Wang   +5 more
wiley   +1 more source

Minutes: Strategic Enrollment Management Subcommitte, February 13, 2017

open access: yes, 2017
University of Minnesota Duluth. Strategic Enrollment Management Subcommitte. (2017). Minutes: Strategic Enrollment Management Subcommitte, February 13, 2017.
University of Minnesota Duluth. Strategic Enrollment Management Subcommitte
core  

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy